Safety and Efficacy of an Baypure Exfoliating AHA-BHA-PHA Serum in Reducing Pigmentation and Tan

An Open-Label Clinical Study to Evaluate the Efficacy of an Baypure Exfoliating AHA-BHA-PHA Serum in Reducing Pigmentation and Tan - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2026/04/107806

Enrollment

Registered

2026-04-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Exfoliating AHA-BHA-PHA Serum: Frequency: 3 times per week, Apply a thin layer on clean, dry skin, Leave for 15-20 minutes, Gently rub off/wash off, Follow with a moisturi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female subjects aged 18 45 years 2. Presence of visible skin concerns such as: (Pigmentation, Tanning, Dark spots, Uneven skin tone, Mild to moderate blemishes/acne marks) 3. Generally healthy skin in the test area (face) 4. Willing to avoid use of other exfoliating or active treatments during the study 5. Willing to follow study instructions and attend all visits 6. Able to provide written informed consent 7. Female subjects of childbearing potential must have a negative pregnancy test

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women 2. Known allergy or hypersensitivity to AHA, BHA, PHA, or any formulation ingredient. 3. Presence of:(Active skin infections, Open wounds or cuts, Severe acne or dermatological conditions (eczema, psoriasis, dermatitis) 4. History of skin cancer or other major dermatological disorders 5.Use of systemic or topical treatments that may interfere with results, such as: o Retinoids o Steroids o Chemical peels or exfoliation treatments (within last 2 4 weeks) 6. Participation in another clinical study within the past 30 60 days 7. Subjects with highly sensitive or reactive skin prone to irritation 8. Any condition which, in the investigator s opinion, may affect study outcomes or subject safety

Design outcomes

Primary

Measure	Time frame
1. Change in Skin dark spots 2. Change in Skin Sebum 3. Change in Skin lightness 4. Change in Skin Pigmentation 5. Change in Dermatological Evaluation 6.HD Imaging 7. Change in Hydration 8. Change in TEWLTimepoint: At Day 0, 30 min, Day 7, Day 14, Day 21 & Day 28	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results